Loading company…
Thabor Therapeutics develops antibody treatments for chronic mucosal inflammatory diseases.
Thabor Therapeutics develops treatments for chronic mucosal inflammatory diseases, including Crohn’s disease and ulcerative colitis. Based in Paris, France, the company raised EUR 2 million in seed funding in July 2022, led by Bpifrance, to support research and development of monoclonal antibodies and an IND application.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in